Evidence map›Paper›PMID 41049271›Full record

ArticleIDCases2025

Seraph® 100 Microbind® utilization in immunocompromised toddler with adenovirus viremia in conjunction with continuous renal replacement therapy and extracorporeal membrane oxygenation.

Guyu Li, Christian Hanna, Laura M Dinnes, Wendy A Allen-Rhoades, Mira A Kohorst, Emily R Levy, Charlotte S Van Dorn, Ziyuan Zhang, James T Gaensbauer

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in IDCases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Novel extracorporeal therapies in children.Pediatric nephrology (Berlin, Germany) · 2026
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Guyu LiDivision of Pediatric Infectious Diseases, Department of Pediatrics, Mayo Clinic, Rochester, MN, USA.
Christian HannaDivision of Pediatric Nephrology and Hypertension, Department of Pediatrics, Mayo Clinic, Rochester, MN, USA.
Laura M DinnesDepartment of Pharmacy, Mayo Clinic, Rochester, MN, USA.
Wendy A Allen-RhoadesDivision of Pediatric Hematology/Oncology/Bone Marrow Transplant, Department of Pediatrics, Mayo Clinic, Rochester, MN, USA.
Mira A KohorstDivision of Pediatric Hematology/Oncology/Bone Marrow Transplant, Department of Pediatrics, Mayo Clinic, Rochester, MN, USA.
Emily R LevyDivision of Pediatric Infectious Diseases and Division of Pediatric Critical Care Medicine, Department of Pediatrics, Mayo Clinic, Rochester, MN, USA.
Charlotte S Van DornDivision of Pediatric Cardiology and Division of Pediatric Critical Care Medicine, Department of Pediatrics, Mayo Clinic, Rochester, MN, USA.
Ziyuan ZhangDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
James T GaensbauerDivision of Pediatric Infectious Diseases, Department of Pediatrics, Mayo Clinic, Rochester, MN, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Seraph® 100 Microbind® is an extracorporeal, sorbent hemoperfusion device intended to adsorb pathogens when integrated into extracorporeal circuits. We describe the use of Seraph 100 in an 18-month-old immunocompromised toddler with adenovirus viremia in conjunction with continuous renal replacement therapy and extracorporeal membrane oxygenation.

Indexed as

AdenovirusBone marrow transplantationExtracorporeal blood purification techniquesPediatrics

Identifiers

PMID41049271
PMCPMC12493244

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.